Browsing Tag
FcRn
2 posts
argenx wins EU approval for subcutaneous VYVGART in CIDP, ending 30-year innovation drought in treatment
argenx gains EU approval for subcutaneous VYVGART in CIDP, reshaping autoimmune neurology care with a novel self-injection biologic.
June 21, 2025
Alexion Pharmaceuticals to acquire Syntimmune for $1.2bn to boost rare disease drug pipeline
In a significant move within the pharmaceutical industry, Alexion Pharmaceuticals, a leading global biopharma company, has announced its…
September 30, 2018